|
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer Clinical research trials and Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer. Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer  Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
For Condition: stage 4 breast cancer,recurrent breast cancer,Male Breast Cancer
Status: Recruiting
Sponsor(s): Dana-Farber/Harvard Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer.
Details: OBJECTIVES: - Determine the safety, tolerability, and maximum tolerated dose of flavopiridol when combined with trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer. - Determine the dose of flavopiridol necessary to achieve a target plasma level of 300-500 nanomoles/L when combined with a fixed dose of trastuzumab in these patients. - Assess the feasibility of measuring cyclin D1 in circulating tumor cells and tissue biopsies before and after this regimen as a surrogate marker of flavopiridol activity in these patients. - Monitor target activity of this regimen in plasma, circulating tumor cells, and tissue biopsies from these patients. OUTLINE: This is a multicenter, dose-escalation study of flavopiridol. Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose is determined (MTD). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 10 patients receives flavopiridol at the MTD and trastuzumab on the once weekly schedule to assess the true toxicity rate. A second cohort of 10 patients receives flavopiridol at the MTD and trastuzumab once every 21 days to assess the tolerability of this schedule. PROJECTED ACCRUAL: A total of 30-50 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed stage IV breast cancer - Patients without histologic or cytologic confirmation of metastatic disease must have unequivocal evidence of metastasis by physical examination or radiologic study - Primary tumor or metastasis HER2-positive by one of the following: - Immunohistochemistry (3+ positive using the DAKO Herceptest or the CB-11 antibody) - Fluorescence in situ hybridization (positive by either the Vysis Pathvysion™ method or the Ventana INFORM™ method) - Measurable or evaluable disease - No active brain metastases or leptomeningeal carcinomatosis - Previously treated CNS metastases allowed provided there are no active symptoms from the CNS disease - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Male or female Menopausal status: - Not specified Performance status: - ECOG 0-1 OR - Karnofsky 70-100% Life expectancy: - More than 6 months Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 mg/dL - AST/ALT no greater than 3 times upper limit of normal Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - LVEF at least 50% by echocardiogram or nuclear scintigraphy (e.g., MUGA scan or radionuclide ventriculography) - No acute changes on electrocardiogram - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Other: - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - Prior grade 1 or 2 allergic reactions to trastuzumab (Herceptin) allowed if these reactions did not prevent further administration - No prior grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biological composition to study agents - No contraindication to warfarin or other warfarin products - No other uncontrolled concurrent illness - No ongoing or active infection - No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy: - No more than 2 prior trastuzumab-containing regimens for metastatic disease Chemotherapy: - No more than 3 prior chemotherapy regimens for metastatic disease - No other concurrent chemotherapy Endocrine therapy: - Prior hormonal therapy in the adjuvant or metastatic setting allowed - Leuprolide initiated prior to study allowed provided therapy continues throughout study - No other concurrent hormonal therapy Radiotherapy: - At least 1 week since prior radiotherapy for metastatic or early-stage breast cancer - No concurrent radiotherapy - Whole brain radiotherapy or stereotactic radiosurgery for brain metastases allowed provided study therapy is held during and for 1 week after radiotherapy Surgery: - Not specified Other: - Recovered from prior anticancer treatments - No other concurrent experimental treatments - Concurrent bisphosphonates initiated before study allowed - Concurrent bisphosphonates initiated during study allowed provided there has been no evidence of progressive disease and the bone sites do not constitute the only sites of evaluable disease
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LyndsayHarris, Study Chair, Dana-Farber/Harvard Cancer Center
Massachusetts General Hospital Cancer Center *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting W. Younger 617-726-8698
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Lyndsay Harris 617-632-6363
Beth Israel Deaconess Medical Center *Recruiting*
Boston, Massachusetts, 02215
United States
Recruiting Steven Come 617-667-4599
Additional Information:
Study ID Numbers: CDR0000069385; NCI-5867,DFCI-01177
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00039455
Other Recurrent Breast Cancer Studies:
1. Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
2. Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
3. Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
4. Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
5. Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Related Studies:
Other recurrent breast cancer Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
|
|
|
|
|
|
|
|
